BC Platforms partners with Australian Tissue Bank to improve breast cancer treatment

pharmafile | April 13, 2021 | News story | Manufacturing and Production Cancer, data 

BC Platforms have announced a data partnership with the Australian Breast Cancer Tissue Bank (ABCTB) for its BCRQUEST.com Global Data Partner Network, aimed towards improving the treatment outcomes of patients with breast cancer.

The ABCTB tissue bank is hosted at the University of Sydney’s Westmead Institute for Medical Research and has a substantial collection of tissue samples going back to 2006, including over 10,000 samples from 5,000 participants as well as their linked associated treatment and clinical data.

The collection includes cancerous and normal tissue samples supporting studies ranging from the identification of common gene variants in breast cancer, to using machine-learning algorithms to distinguish subtypes and polygenic risk scores to predict breast cancer.

Jennifer Cubino, COO, Customer Success and Data Sciences at BC Platforms, said: “Our global footprint of the Global Data Partner Network BCRQUEST.com is rapidly growing as organisations recognise the value of rapid access to expertly curated and carefully governed patient data which is otherwise difficult to obtain.

“We welcome ABCTB to our global coalition of data partners, enabling deep data access that can improve outcomes for affected patients.”

The Global Data Partner Network BCRQUEST.com is a healthcare network that provides a streamlined solution for researchers to efficiently access holistic data, improving research insight generation.

The company has said that the platform and its supporting framework will help to enable collaboration between pharmaceutical institutions, healthcare and academic researchers whilst strictly adhering to global and local data privacy and security regulations.

Professor Christine Clarke, Emeritus Professor at The University of Sydney, The Westmead Institute for Medical Research, and Chair of the Australian Breast Cancer Tissue Bank, said, “Our collaboration with BC Platforms is a new pathway to facilitate worldwide access to the ABCTB resource.

“We are excited about the potential to translate current research knowledge into clinical practice, including investigating the molecular basis of disease and gaining a deeper understanding of the genomic predictors of response to drugs and potential new therapeutics”.

Kat Jenkins

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to …

Latest content